We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Forest Gets Untitled Letter After Reps Downplay Weight-Loss Risks
Forest Gets Untitled Letter After Reps Downplay Weight-Loss Risks
August 10, 2012
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.